Huisong was Granted Invention Patent Authorization Related to Yuxingcao Qinlan Heji

On November 3, 2023, Zhejiang Huisong Pharmaceuticals Co., Ltd. was granted the invention patent authorization for a quantitative determination method of nucleosides in Yuxingcao Qinlan Heji Intermediate. The invention discloses a method for quantative determination of nucleosides in Yuxingcao Qinlan Heji Intermediate. The nucleosides of the intermediate include uridine and guanosine.
1)Prepare the test solution with Yuxingcao Qinlan Heji Intermediate. Prepare the reference solution using uridine reference standard and guanosine reference standard.
2)Perform liquid chromatography analysis on the reference solution and the test solution, and prepare the Waters Atlantis T3 as chromatographic column; Use water as mobile phase A and acetonitrile as mobile phase B for gradient elution.
3)Record the chromatogram, calculating by the peak area to comply with external standard method to determine the content of nucleosides in test solution.
This method, which has the characteristics of short analysis time, low instrument requirement, simple process, with an accurate and reliable result, can fill the gap in the existing technology in quality control of medicinal active ingredients and intermediates.